Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. No therapies currently exist that either directly target the heart or the fibrotic process itself. We have discovered a heart specific regulator of fibrosis – the long noncoding RNA, Wisper. By using our first-in-class proprietary approach to target Wisper, we are able to block myocardial fibrosis and treat heart failure in pre-clinical animal models.

HaYa Therapeutics is a member of StartLab